amifostine anhydrous has been researched along with Experimental Neoplasms in 41 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of treatments with the hypoxic cell radiosensitizers misonidazole (MISO), SR-2508, RSU-1069, and with the radioprotector WR-2721 on spontaneously disseminated Lewis lung carcinoma (LLC) and B16 melanoma (B16M) was investigated." | 7.67 | Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice. ( Chapman, JD; Kanclerz, A, 1988) |
| "The effect of treatments with the hypoxic cell radiosensitizers misonidazole (MISO), SR-2508, RSU-1069, and with the radioprotector WR-2721 on spontaneously disseminated Lewis lung carcinoma (LLC) and B16 melanoma (B16M) was investigated." | 3.67 | Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice. ( Chapman, JD; Kanclerz, A, 1988) |
| "The influence of tumor size on the ability of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) or misonidazole (MISO) to alter cyclophosphamide (CY) antitumor activity was investigated, using a chemically induced fibrosarcoma (FSA) and a spontaneous fibrosarcoma (NFSA) in C3Hf/Kam mice." | 3.66 | Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide. ( Hunter, N; Ito, H; Milas, L, 1983) |
| "Pretreatment with misonidazole at doses of 300-900 mg/kg yielded tumor sensitization with a DMF of 0." | 1.27 | Radioprotection combined with hypoxic sensitization during radiotherapy of a solid murine tumor. ( Beach, JL; Grigsby, PW; Mendiondo, OA, 1983) |
| " Dose modification factors (DMFs) were calculated as ratios of LD50 values." | 1.27 | Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution. ( Anderson, K; Krohn, KA; Mahler, P; Menard, T; Nelson, NJ; Rasey, JS, 1984) |
| " WR-2721 can, therefore, increase the effectiveness of cisplatin therapy through selective protection against the toxic side effects of chemotherapy." | 1.26 | Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. ( Culo, F; Yuhas, JM, 1980) |
| " The toxic LD50/30 was 3574 mg/kg." | 1.26 | Toxicity and radiation protective effect of WR-77913 in BALB/c mice. ( Connor, AM; Grigsby, P; Mendiondo, OA, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (78.05) | 18.7374 |
| 1990's | 7 (17.07) | 18.2507 |
| 2000's | 1 (2.44) | 29.6817 |
| 2010's | 1 (2.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Polyatskaya, Y | 1 |
| Nelson, NS | 1 |
| Rodriguez, JJ | 1 |
| Zheutlin, AR | 1 |
| Deshpande, SS | 1 |
| Felice, PA | 1 |
| Donneys, A | 1 |
| Buchman, SR | 1 |
| Colevas, AD | 1 |
| Brown, JM | 2 |
| Hahn, S | 1 |
| Mitchell, J | 1 |
| Camphausen, K | 1 |
| Coleman, CN | 1 |
| Travis, EL | 1 |
| Utley, JF | 2 |
| Seaver, N | 1 |
| Newton, GL | 1 |
| Fahey, RC | 1 |
| Williams, MV | 1 |
| Rojas, A | 2 |
| Denekamp, J | 2 |
| Yuhas, JM | 5 |
| Culo, F | 2 |
| Spellman, JM | 1 |
| Phillips, TL | 1 |
| Millar, JL | 1 |
| McElwain, TJ | 1 |
| Clutterbuck, RD | 1 |
| Wist, EA | 1 |
| Stewart, FA | 1 |
| Mendiondo, OA | 2 |
| Connor, AM | 1 |
| Grigsby, P | 1 |
| Milas, L | 3 |
| Ito, H | 2 |
| Hunter, N | 2 |
| Grigsby, PW | 1 |
| Beach, JL | 1 |
| Moldenhauer, H | 1 |
| Rose, H | 1 |
| Saul, G | 1 |
| Wolf, G | 1 |
| Kehrberg, G | 1 |
| Peters, LJ | 1 |
| Rasey, JS | 5 |
| Nelson, NJ | 1 |
| Mahler, P | 1 |
| Anderson, K | 1 |
| Krohn, KA | 4 |
| Menard, T | 1 |
| Isoda, H | 1 |
| Akagi, K | 1 |
| Hasegawa, T | 1 |
| Tanaka, Y | 1 |
| Kihara, T | 1 |
| Sakata, S | 1 |
| Ikeda, M | 1 |
| Lenoble, M | 1 |
| Capizzi, RL | 2 |
| Marlowe, C | 1 |
| Waddell, WJ | 1 |
| Yurconic, M | 1 |
| Kligerman, MM | 2 |
| West, G | 1 |
| Peterson, DF | 1 |
| Chapman, JD | 2 |
| Urtasun, RC | 1 |
| Moulder, JE | 1 |
| Lo, PS | 1 |
| Fischer, JJ | 1 |
| Peters, GJ | 1 |
| van der Wilt, CL | 1 |
| Gyergyay, F | 1 |
| van Laar, JA | 1 |
| Treskes, M | 1 |
| van der Vijgh, WJ | 1 |
| Pinedo, HM | 1 |
| Floersheim, GL | 1 |
| Bieri, A | 1 |
| Coia, LR | 1 |
| Brown, DQ | 2 |
| Bellnier, DA | 1 |
| Dougherty, TJ | 1 |
| Kanclerz, A | 1 |
| Murray, D | 1 |
| Brock, WA | 1 |
| Meyn, RE | 1 |
| Shaw, LM | 1 |
| Glover, D | 1 |
| Turrisi, A | 1 |
| Bonner, HS | 1 |
| Norfleet, AL | 1 |
| Weiler, C | 1 |
| Glick, JH | 1 |
| Grunbaum, Z | 1 |
| Menard, TW | 2 |
| Spence, AM | 2 |
| Begg, AC | 1 |
| Terry, NH | 1 |
| Nakano, Y | 1 |
| Biscay, P | 1 |
| Lespinasse, F | 1 |
| Oiry, J | 1 |
| Huczkowski, J | 1 |
| Imbach, J | 1 |
| Malaise, EP | 1 |
| Guichard, M | 1 |
| Magee, S | 1 |
| Nelson, N | 1 |
| Chin, L | 1 |
11 reviews available for amifostine anhydrous and Experimental Neoplasms
| Article | Year |
|---|---|
Development of investigational radiation modifiers.
Topics: Amifostine; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phas | 2003 |
The oxygen dependence of protection by aminothiols: implications for normal tissues and solid tumors.
Topics: Amifostine; Animals; Bone Marrow; Dose-Response Relationship, Drug; Dose-Response Relationship, Radi | 1984 |
Sensitizers and protectors in clinical oncology.
Topics: Alkylating Agents; Amifostine; Animals; Drug Synergism; Humans; Mice; Misonidazole; Neoplasms; Neopl | 1981 |
[Modification of the radiation effects for overcoming radiation-resistant hypoxic tumor tissue].
Topics: Amifostine; Animals; Central Nervous System Diseases; Dogs; Humans; Hyperthermia, Induced; In Vitro | 1983 |
[Amifostine: current and future applications in cytoprotection].
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Disease Models, Animal; Drug Tolerance; Hem | 1996 |
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).
Topics: Amifostine; Animals; Antineoplastic Agents; Mice; Neoplasms, Experimental; Radiation Injuries; Radia | 1996 |
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Topics: Amifostine; Animals; Antineoplastic Agents; Cytoprotection; Drug Evaluation, Preclinical; Humans; Me | 1999 |
Amifostine.
Topics: Amifostine; Animals; Clinical Trials as Topic; Humans; Neoplasms; Neoplasms, Experimental; Radiation | 1999 |
Radioprotectors in tumor radiotherapy: factors and settings determining therapeutic ratio.
Topics: Amifostine; Animals; Cells, Cultured; Ditiocarb; Humans; Immune Tolerance; Neoplasm Metastasis; Neop | 1988 |
Pharmacokinetics of WR-2721.
Topics: Amifostine; Animals; Humans; Hydrolysis; Neoplasms; Neoplasms, Experimental; Organothiophosphorus Co | 1988 |
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione | 1985 |
2 trials available for amifostine anhydrous and Experimental Neoplasms
| Article | Year |
|---|---|
[Amifostine: current and future applications in cytoprotection].
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Disease Models, Animal; Drug Tolerance; Hem | 1996 |
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione | 1985 |
30 other studies available for amifostine anhydrous and Experimental Neoplasms
| Article | Year |
|---|---|
Prophylactic amifostine prevents a pathologic vascular response in a murine model of expander-based breast reconstruction.
Topics: Amifostine; Angiography; Animals; Breast Neoplasms; Disease Models, Animal; Dose-Response Relationsh | 2016 |
Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
Topics: Amifostine; Animals; Male; Mercaptoethylamines; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; | 1984 |
Tumor sensitization and protection: influence of stromal injury on estimates of dose modification.
Topics: Amifostine; Animals; Dose-Response Relationship, Radiation; Fibrosarcoma; Mice; Misonidazole; Neopla | 1984 |
Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.
Topics: Amifostine; Animals; Blood Urea Nitrogen; Body Weight; Cisplatin; Dose-Response Relationship, Drug; | 1980 |
The role of WR-2721 in radiotherapy and/or chemotherapy.
Topics: Alkylating Agents; Amifostine; Animals; Breast Neoplasms; Cyclophosphamide; Humans; In Vitro Techniq | 1980 |
The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721).
Topics: Amifostine; Animals; Colony-Forming Units Assay; Female; Hematopoietic Stem Cells; Male; Melanoma; M | 1982 |
Interaction of misonidazole and WR-2721--II. Modification of tumour radiosensitization.
Topics: Amifostine; Animals; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Interactio | 1983 |
Toxicity and radiation protective effect of WR-77913 in BALB/c mice.
Topics: Amifostine; Animals; Bone Marrow; Dose-Response Relationship, Radiation; Female; Mice; Mice, Inbred | 1982 |
Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
Topics: Amifostine; Animals; Cyclophosphamide; Drug Interactions; Drug Therapy, Combination; Extremities; Fe | 1983 |
Efficacy testing of WR-2721 in Great Britain everything is black and white at the gray lab.
Topics: Amifostine; Animals; Evaluation Studies as Topic; Mice; Mice, Inbred BALB C; Neoplasms, Experimental | 1983 |
Radioprotection combined with hypoxic sensitization during radiotherapy of a solid murine tumor.
Topics: Amifostine; Animals; Cell Line; Dose-Response Relationship, Drug; Drug Interactions; Female; Mice; M | 1983 |
Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721.
Topics: Amifostine; Animals; Carcinoma; Dose-Response Relationship, Radiation; Female; Fibrosarcoma; Male; M | 1984 |
Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution.
Topics: Amifostine; Animals; Cesium Radioisotopes; Dose-Response Relationship, Radiation; Female; Gamma Rays | 1984 |
Detection of an increase in ascorbate radical in an irradiated experimental tumour system using ESR.
Topics: Amifostine; Animals; Ascorbic Acid; Dose-Response Relationship, Radiation; Electron Spin Resonance S | 1995 |
Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2.
Topics: Amifostine; Animals; Brain; Kidney; Liver; Mice; Mice, Inbred BALB C; Myocardium; Neoplasm Transplan | 1976 |
Combined use of radioprotective and radiosensitizing drugs in experimental radiotherapy.
Topics: Amifostine; Animals; Cell Line; Cell Survival; Dose-Response Relationship, Radiation; Drug Therapy, | 1977 |
The application in radiation therapy of substances which modify cellular radiation response.
Topics: Amifostine; Animals; Drug Evaluation; Drug Therapy, Combination; Humans; Metronidazole; Neoplasms; N | 1977 |
Effect of the radioprotective drugs MEA, DMSO, and WR-2721 on tumor control and skin tolerance in the rat.
Topics: Amifostine; Animals; Dimethyl Sulfoxide; Female; Male; Mercaptoethylamines; Neoplasms, Experimental; | 1977 |
Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine.
Topics: Amifostine; Animals; Bone Marrow; Drug Tolerance; Female; Lethal Dose 50; Lung Neoplasms; Mechloreth | 1979 |
Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil | 1992 |
Further studies on selective radioprotection by organic zinc salts and synergism of zinc aspartate with WR 2721.
Topics: Acetates; Acetic Acid; Amifostine; Animals; Blood Cell Count; Drug Synergism; Female; Histidine; Mal | 1990 |
Protection of bone marrow by WR-2721 after fractionated irradiation.
Topics: Amifostine; Animals; Bone Marrow; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Organothiophospho | 1989 |
Protection of murine foot tissue and transplantable tumor against Photofrin-II-mediated photodynamic sensitization with WR-2721.
Topics: Amifostine; Animals; Dihematoporphyrin Ether; Drug Evaluation, Preclinical; Female; Foot; Hematoporp | 1989 |
Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
Topics: Amifostine; Animals; Etanidazole; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Misonida | 1988 |
Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913).
Topics: Amifostine; Animals; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Orga | 1985 |
Stromal radiosensitivity: influence of tumour type on the Tumour Bed Effect assay.
Topics: Adenocarcinoma; Amifostine; Animals; Dose-Response Relationship, Radiation; Mice; Mice, Inbred CBA; | 1985 |
[Effect of combined radiotherapy, hyperthermia, radioprotective agent and hypoxic cell sensitizer on mice testis--testicular weight as indicator of the combined effect].
Topics: Amifostine; Animals; Combined Modality Therapy; Hyperthermia, Induced; Male; Mice; Misonidazole; Neo | 1985 |
Radiobiological evaluation of a newly synthesized cysteamine derivative.
Topics: Amifostine; Animals; Cysteamine; Humans; Mice; Neoplasms, Experimental; Radiation-Protective Agents | 1986 |
Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors.
Topics: Amifostine; Animals; Mice; Neoplasms, Experimental; Radiation-Protective Agents; Tissue Distribution | 1986 |
Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor.
Topics: Amifostine; Animals; Cell Survival; Male; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Organothi | 1986 |